Construction method of infectious hematopoietic necrosis virus-aeromonas salmonicida vector bivalent vaccine

By expressing IHNV G protein on Aeromonas salmoniae, a double-linked vaccine was constructed, which solved the problem that the IHNV vaccine could not be added to the multi-linked vaccine, and provided protection for rainbow trout to prevent Aeromonas salmon and achieved oil emulsification The long-term effect of immunity fills the gap in the development of Aeromonas salmonic vaccine.

CN119015405APending Publication Date: 2024-11-26YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411092302.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The rainbow trout breeding industry faces two major pathogenic threats: infectious hematopoietic organ necrosis virus (IHNV) and Aeromonas salmon. The existing IHNV vaccine cannot be added to the multi-link vaccine as an antigen, which limits its application, and Aeromonas salmonas salmonas vaccine R&D is lagging behind and there is a lack of effective prevention and control measures.

Method used

AAV salmonas as a vector expresses IHNV G protein to construct a dual vaccine for infectious hematopoietic organ necrosis virus-AAV salmonas vector. The IHNV G protein is used to optimize codons, PCR amplification and electroconversion methods Genes introduced Aeromonas salmoniae to prepare an oil emulsification vaccine, combined with MontanideTM ISA 763A VG adjuvant, to achieve heterologous expression and immune protection.

Benefits of technology

This double-linked vaccine not only protects rainbow trout from Aeromonas infection, but also produces IHNV neutralizing antibodies. It has important application value, realizes the long-term effect of oil emulsification immunity, and effectively solves the multi-linked vaccine. Made a puzzle.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015405A_ABST
    Figure CN119015405A_ABST
Patent Text Reader

Abstract

Infectious haematopoietic necrosis virus (IHNV) and aeromonas salmonicida are two important pathogens of rainbow trout, in order to solve the threat of the two main pathogens to the rainbow trout breeding industry, the research takes the aeromonas salmonicida as a carrier, IHNV G protein is expressed, a multi-combined vaccine aiming at the two pathogens of the IHNV and the aeromonas salmonicida is constructed, and in order to solve the threat of the two main pathogens to the rainbow trout breeding industry, the IHNV and the aeromonas salmonicida are combined to form the rainbow trout vaccine. The infectious hematopoietic necrosis virus-aeromonas salmonicida vector bivalent vaccine has the advantages that the immune protection effect of the infectious hematopoietic necrosis virus-aeromonas salmonicida vector bivalent vaccine is analyzed, the technical support is provided for the culture health of oncorhynchus mykiss in China, and the infectious hematopoietic necrosis virus-aeromonas salmonicida vector bivalent vaccine
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the fields of microbiology and pathology, and in particular to a construction method of an infectious hematopoietic necrosis virus-Aeromonas salmonicida vector bivalent vaccine. Background Art

[0002] Rainbow trout (Oncorhynchus mykiss) is an important farmed cold-water fish in the world. It is also farmed on a large scale in Gansu, Qinghai and Xinjiang in my country. In recent years, with the expansion of rainbow trout farming scale and the increase in production, diseases have gradually become an important limiting factor in the development of the industry, seriously affecting the healthy development of my country's rainbow trout farming industry. Among them, infectious hematopoietic necrosis virus (IHNV) and Aeromonas salmonicida are two important pathogens of rainbow trout.

[0003] IHNV mainly causes infectious hematopoietic necrosis (IHN) in salmon and trout, leading to necrosis of the kidneys, spleen and hematopoietic tissues of fish, with a mortality rate of over 90%, causing huge economic losses to the global salmon and trout farming industry. The IHNV genome encodes five structural proteins and one non-structural protein NV. Among them, glycoprotein, also known as G protein, is the only surface protein of the virus and the main antigenic determinant. It can stimulate the body to produce neutralizing antibodies and induce cellular immunity. It plays an important role in viral pathogenicity and immune response. At present, research on IHNV genetic engineering vaccines mainly focuses on G protein.

[0004] Aeromonas salmonicida belongs to the genus Aeromonas and is a facultative anaerobic Gram-negative short rod that can cause furunculosis or ulcer disease in many fish species. At present, the international commercialization of Aeromonas salmonicida oil-emulsified inactivated vaccine technology for salmon and trout is very mature, but my country still relies on antibiotics as the main means of prevention and control, and the development of vaccine for Aeromonas salmonicida has become particularly urgent.

[0005] Vaccines are the most effective means of preventing rainbow trout diseases. Various commercial vaccines for rainbow trout diseases have been widely used internationally, such as DNA vaccines for IHNV, subunit vaccines for IPNV, recombinant vaccines for infectious salmonanaemia virus (ISAV), and oil-adjuvanted vaccines for Aeromonas salmonicida. As salmon and trout face threats from a variety of pathogens, multi-component vaccines with vegetable oil or mineral oil as adjuvants are the main types of commercial vaccines. Currently, there is only one DNA vaccine for IHNV on the market, which is injected intramuscularly in the form of an aqueous solution and cannot be added as one of the antigens to multi-component vaccines, which brings great difficulties to the application of IHNV vaccines.

[0006] The types of IHNV vaccines reported so far include DNA vaccines, inactivated vaccines, and subunit vaccines. For example, Ballesteros et al. connected the G genes of IHNV and VHSV to pcDNA 3, respectively, and successfully constructed two DNA vaccines with immune protection rates of 96% and 94%. Wu et al. used CpG sequences as adjuvants to construct a DNA vaccine of the IHNV G gene. The expression of Mx-1 and IFN-γ was significantly upregulated at the early stage of infection, stimulating the fish to produce specific IgM antibodies and neutralizing antibodies. Lin et al. used Montanide GEL 02PR as a colloidal adjuvant to prepare an inactivated IHNV vaccine with an immune protection period of more than 285 days, which has a wide range of application potential. In terms of recombinant protein vaccines, the protein vaccine of IHNV is mainly based on surface glycoproteins. In terms of recombinant protein vaccines, the protein vaccine of IHNV is mainly based on surface glycoproteins. Sun et al. used rainbow trout CK 6 chemokine protein and IHNV truncated G protein to construct a secretory recombinant Lactobacillus casei oral vaccine with a relative immune protection rate of 66.67%. Wang Yanxue prepared a recombinant subunit vaccine by truncating and recombinantly expressing the IHNV-G protein gene fragment, with a relative protection rate of 60%.

[0007] Neutralizing antibodies are one of the important indicators for evaluating the immune protection effect of viral vaccines. Studies have shown that the efficacy of IHNV vaccines can be evaluated by detecting the serum antibody levels of vaccinated rainbow trout. For example, after Li et al. immunized rainbow trout with the IHN-IPN bivalent vaccine constructed using adenovirus as a vector, the neutralizing antibody level in the immunized group continued to increase. Zhao et al. successfully displayed IHNV glycoprotein on the surface of brewer's yeast using yeast surface display technology to make an oral vaccine. After immunizing rainbow trout, the serum anti-IHNV neutralizing antibody titer was significantly higher than that of the control group. Summary of the invention

[0008] In order to solve the threat of the above two major pathogens to rainbow trout aquaculture, this study used Aeromonas salmonicida as a vector to express IHNV G protein, constructed a multi-vaccine against IHNV and Aeromonas salmonicida, and analyzed its immune protection effect, in order to provide technical support for the health of rainbow trout aquaculture in my country. We proposed a construction method of an infectious hematopoietic necrosis virus-Aeromonas salmonicida vector binary vaccine, and the present invention is achieved through the following technical solutions:

[0009] To achieve the above object, the present invention provides a method for constructing an infectious hematopoietic necrosis virus-Aeromonas salmonicida vector bivalent vaccine, characterized in that the construction method is as follows:

[0010] a. Based on the J-type IHNV-G protein gene sequence (SEQ ID NO: MT242597), codon optimization was performed based on the codon preference of the Aeromonas salmonicida genome and the optimized gene IHNV-GA was synthesized.

[0011] b. Design of optimized primer sequences for IHNV-G protein gene fragment

[0012] c. Using the optimized gene IHNV-GA as a PCR template to amplify the IHNV-G protein gene

[0013] d. The amplified product was detected by 1.0% agarose gel electrophoresis, recovered and connected to the pGEX-4T-1 vector and sequenced to obtain the IHNV G protein expression plasmid pGEX-4T-1-G

[0014] e. Use electroporation to transform the recombinant plasmid pGEX-4T-1-G into competent cells SC18032201 to obtain the successfully transformed positive transformant SC18032201-G

[0015] f. Induce SC18032201-G to express recombinant protein under the optimal induction expression conditions, inactivate with 5‰ formaldehyde for 24 hours, and dilute with PBS to a final concentration of about 1×10 9 cell / mL, as Montanide TM ISA 763A VG as adjuvant to prepare oil-emulsified vaccine

[0016] Preferably, the above-mentioned optimized gene IHNV-GA sequence is

[0017]

[0018] Preferably, the above primer sequences are:

[0019] Upstream primer IHNV-of-pGEX-4T-1-for-f: 5′-CGCGTGGATCCCCGGCAGACCGTCCCGCCGGATAC-3′,

[0020] Downstream primer

[0021] IHNV-of-pGEX-4T-1-for-r:5′-GTCGACCCGGGAATTTTATCAAGATGATGGTGGTGATGATGCAAGC-3′.

[0022] Preferably, the amplification procedure of the above PCR is:

[0023] The amplification program was as follows: pre-denaturation at 98°C for 1 min; denaturation at 98°C for 10 s; annealing at 58°C for 5 s, extension at 72°C for 15 s, 35 cycles; and full extension at 72°C for 7 min.

[0024] Preferably, the optimal protein induction conditions for the above recombinant bacteria SC18032201-G are: 0.2 mM IPTG, 28° C. induction expression for 8 h.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] (1) In this study, the strain SC18032201 of Aeromonas salmonicida subsp. salmonicida was used as an expression vector to heterologously express the IHNV surface antigen glycoprotein. The constructed bivalent vector vaccine can not only protect rainbow trout from infection with Aeromonas salmonicida, but also produce IHNV neutralizing antibodies.

[0027] (2) It can be used as an oil-emulsified vaccine to immunize, and can be combined with the most widely used salmon and trout vaccine to make a multi-component vaccine, which has important application value in the prevention and control of salmon and trout diseases;

[0028] (3) An economical and effective method for preparing a bivalent vaccine;

[0029] (4) The first long-acting infectious hematopoietic necrosis virus-Aeromonas salmonicida vectored bivalent vaccine that can achieve oil-emulsified immunity. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 It is the PCR amplification product of the IHNV-G protein gene of the present invention; M: DNA Marker DL2000; 1: negative control; 2-4: are the PCR amplification products of the G gene;

[0031] Figure 2PCR identification of the recombinant plasmid bacterial solution of the present invention; M: DNAMarker DL2000; 1-4: PCR amplification products of the recombinant plasmid pGEX-4T-1-G;

[0032] Figure 3 The identification result of the recombinant plasmid pGEX-4T-1-G of the present invention electroporated Aeromonas salmonicida; M: DNAMarkerDL2000; 1-4: repeats;

[0033] Figure 4 Western-blotting identification of the recombinant protein of the present invention; M: protein marker (15-130KDa); 1, 2, 3: supernatants after induction of SC18032201-G, SC18032201-pGEX, and wild strain SC18032201; 4, 5, 6: precipitates after induction of SC18032201-G, SC18032201-pGEX, and wild strain SC18032201;

[0034] Figure 5 The protein expression of the recombinant bacteria of the present invention at different temperatures; M: Rainbow 130 broad-spectrum protein marker (15-130KDa); 1, 2, 3, 4: supernatant after induction at 20°C, 24°C, 28°C, and 32°C; 5, 6, 7, 8: precipitate after induction at 20°C, 24°C, 28°C, and 32°C;

[0035] Figure 6 The protein expression of the recombinant bacteria of the present invention at different times; M: Rainbow 130 broad-spectrum protein marker (15-130KDa); 1, 2, 3, 4, 5: supernatant after 4h, 8h, 12h, 16h, 20h of induction; 6, 7, 8, 9, 10: precipitate after 4h, 8h, 12h, 16h, 20h of induction;

[0036] Figure 7 The protein expression of the recombinant bacteria of the present invention under different IPTG concentrations; M: Rainbow 130 broad-spectrum protein Marker (15-130KDa); 1, 2, 3, 4, 5: supernatants after induction with IPTG concentrations of 0.05mM, 0.1mM, 0.2mM, 0.4mM, and 0.8mM; 6, 7, 8, 9, 10: precipitates after induction with IPTG concentrations of 0.05mM, 0.1mM, 0.2mM, 0.4mM, and 0.8mM. DETAILED DESCRIPTION

[0037] The following examples are used to more specifically describe the present invention. It should be understood that the implementation of the present invention is not limited to the following examples, and any modifications or changes made to the present invention fall within the scope of protection of the present invention; and the methods in the following examples, unless otherwise specified, are conventional methods in the art.

[0038] Embodiment 1:

[0039] Strains, plasmids, and experimental fish

[0040] The strain SC18032201 of Aeromonas salmonicida subsp. salmonicida was identified and preserved by our laboratory, and the Escherichia coli DH5α and protein expression plasmid pGEX-4T-1 were preserved by our laboratory. Healthy rainbow trout were purchased from a rainbow trout farm in Linqu, Weifang, Shandong, weighing 53±6.84 g and cultured in a circulating water system of 1 ton of water, with a daily circulation volume of 20 times, a water temperature of 14-16°C, a dissolved oxygen of 8-10 mg / L, and a feeding rate of 1.2%. Before the experiment, 40 fish were randomly selected for bacterial isolation and IHNV virus detection to ensure that the experimental fish were not infected with pathogens.

[0041] Primer design and synthesis

[0042] According to the J-type IHNV G protein gene sequence (sequence number: MT242597), codon optimization was performed based on the codon preference of the Aeromonas salmonicida genome and synthesized (Shanghai Shenggong Biotechnology Co., Ltd.). Primer5.0 was used to design the optimized primer sequence of the IHNV-G protein gene fragment.

[0043] Upstream primer

[0044] IHNV-of-pGEX-4T-1-for:5′-CGCGTGGATCCCCGGCAGACCGTCCCGCC GGATAC-3′,

[0045] Downstream primer

[0046] IHNV-of-pGEX-4T-1-for:5′-GTCGACCCGGGAATTTTATCAAGATGATGGTGGTGATGATGCAAGC-3′

[0047] Synthesized by Paisono.

[0048] Construction of IHNV-G protein expression vector

[0049] The codon-optimized gene was used as a PCR template. Primers IHNV-of-pGEX-4T-1-for and IHNV-of-pGEX-4T-1-rev were selected to amplify the IHNV-G protein gene. The amplification procedure was 98℃ pre-denaturation for 1min; 98℃ denaturation for 10s; 58℃ annealing for 5s, 72℃ extension for 15s, 35 cycles; 72℃ full extension for 7min. The amplified product was detected by 1.0% agarose gel electrophoresis, recovered and connected to the pGEX-4T-1 vector and sequenced to obtain the IHNV G protein expression plasmid pGEX-4T-1-G. The recombinant plasmid pGEX-4T-1-G was transformed into the competent cell SC18032201 by electroporation, and the successful transformation positive transformant SC18032201-G was obtained.

[0050] The IHNV glycoprotein gene was amplified using primers IHNV-of-pGEX-4T-1-for and IHNV-of-pGEX-4T-1-rev to obtain a 1341 bp target fragment of the glycoprotein gene, such as Figure 1 As shown, it was connected with the pGEX-4T-1 plasmid after restriction digestion using a seamless cloning kit, transformed into DH5α competent cells, and then PCR and sequencing were performed for identification, as shown Figure 2 As shown, it indicates that the pGEX-4T-1-G recombinant plasmid was successfully constructed. The recombinant plasmid pGEX-4T-1-G was electroporated into the competent cells of Aeromonas salmonicida SC18032201, and PCR amplification and sequencing verification confirmed that the SC18032201-G vector was successfully constructed. Figure 3 shown.

[0051] Inducible expression of recombinant protein and Western-blotting analysis

[0052] SC18032201-pGEX containing the empty vector pGEX-4T-1 plasmid and the wild strain SC18032201 were used as negative controls for protein induction expression detection. The inclusion bodies after induced expression were dissolved with 8M urea, and the treated protein supernatant and inclusion bodies were subjected to 12% SDS-PAGE gel electrophoresis. After electrophoresis, the samples were transferred to PVDF membranes, and the recombinant proteins were detected by Western Blotting using mouse anti-6×His monoclonal antibody as the primary antibody and HRP-labeled goat anti-mouse IgG as the secondary antibody. The single-factor method was used to optimize the effects of induction temperature, induction time and inducer concentration on protein expression, with only one variable set each time. With a final concentration of 0.1 mM IPTG, the cultures were induced at 20°C, 24°C, 28°C and 32°C for 12 h, and samples were taken for Western Blotting to optimize the induction temperature. With a final concentration of 0.1 mM IPTG, the cultures were induced at 28°C for 4 h, 8 h, 12 h, 16 h and 20 h, and samples were taken for Western Blotting to optimize the induction time. With final concentrations of 0.05, 0.1, 0.2, 0.4 and 0.8 mM IPTG, the cultures were induced at 28°C for 8 h, and samples were taken for Western Blotting to optimize the IPTG concentration.

[0053] After the recombinant bacteria SC18032201-G was induced by IPTG at 28℃ for 12h, the bacterial cells were broken and analyzed by Western-blotting, and the salmonicidal Aeromonas SC18032201-pGEX containing the pGEX-4T-1 plasmid and the wild-type strain SC18032201 were used as controls. The results showed that specific binding bands appeared in the cell fragments of SC18032201-G, while the cell fragments of SC18032201-pGEX containing the pGEX-4T-1 plasmid and the wild-type strain SC18032201 did not show specific bands, such as Figure 4 Western-blotting results showed that IHNV G protein was successfully expressed in SC18032201-G.

[0054] Western-blotting of the recombinant bacteria SC18032201-G at 20℃, 24℃, 28℃, and 32℃ for 12h showed that the target protein could not be successfully expressed at 20℃, a small amount of target protein could be expressed at 24℃, and a large amount of protein could be expressed at 28℃ and 32℃. However, 32℃ exceeded the optimal growth temperature of Aeromonas salmonicida. Figure 5As shown. Therefore, 28℃ was selected as the optimal temperature for protein induction expression. The induction time was further optimized. Western-blotting results after 4h, 8h, 12h, 16h, and 20h induction of the recombinant bacteria SC18032201-G showed that the expression level of the target protein was the lowest at 4h and the highest at 8h. After 8h, the expression level remained almost unchanged as time went on. Figure 6 As shown. Therefore, 8h was selected as the optimal time for protein induction expression. The recombinant bacteria SC18032201-G were induced with final concentrations of 0.05mM, 0.1mM, 0.2mM, 0.4mM, and 0.8mM IPTG at 28℃ for 8h. Western-blotting showed that the expression level of the target protein was the highest when induced by 0.2mM IPTG, and the expression levels were almost the same when induced by other concentrations of IPTG, as shown in Figure 2. Figure 7 As shown. Therefore, 0.2mM was selected as the optimal IPTG concentration for protein induction expression. Therefore, the optimal protein induction conditions for the recombinant bacteria SC18032201-G were: 0.2mM IPTG, 28℃ induction expression for 8h.

[0055] Vaccine immunization and efficacy evaluation

[0056] Under the optimal induction expression conditions, SC18032201-G was induced to express recombinant protein, inactivated with 5‰ formaldehyde for 24 h, and diluted with PBS to a final concentration of about 1×10 9 cell / mL, as Montanide TM ISA 763A VG was used as an adjuvant to prepare an oil-emulsified vaccine, and a PBS control group was prepared in the same way. 100 healthy rainbow trout were randomly divided into two groups. The immunization group had 50 trout, which were intraperitoneally injected with SC18032201-G bivalent vaccine; the control group had 50 trout, which were intraperitoneally injected with an equal dose of PBS. 45 days after immunization, 10 rainbow trout were randomly selected from each group for tail vein blood collection and serum collection. The remaining rainbow trout in the immunization group and the control group were randomly divided into two groups, with 20 trout in each group. Immersion infection with 1×10 6 CFU / mL salmonicidal Aeromonas SC18032201, observe for 30 days, count the cumulative deaths, and calculate the relative percent survival (RPS): RPS = [1-(CPM of vaccinated fish / CPM of unvaccinated fish)] × 100%.

[0057] 45 days after rainbow trout were immunized with the vaccine via intraperitoneal injection, the immunized group and the control group were immersed in the virus and the number of deaths was recorded every day. The mortality rates of the control group were 35% and 40%, respectively, and no deaths occurred in the immunized group. The relative immune protection rate of the vaccine against Aeromonas salmonicida infection was 100%.

[0058] Table 1 Immune protection of vector vaccines

[0059]

[0060] Serum neutralizing antibody titer determination

[0061] The IHNV virus stock solution was diluted with cell maintenance medium (MEM medium + 2% fetal bovine serum + 1% double antibody) and inoculated into a monolayer of Epithelioma papulosumcyprinid (EPC). After incubation in a 15°C CO2 constant temperature incubator for 1 hour, the culture medium containing the virus was discarded and replaced with 100 μL of cell maintenance medium per well. The cells were cultured at 15°C. The CPE of the virus in all wells was observed every day and the results were recorded for 7 days. The TCID was calculated using the Reed-Muench method. 50 Results: The serum samples in 1.2.4 were serially diluted 2-fold (1:2 to 1:256) with cell maintenance medium and then mixed with 100 TCID 50 The IHNV virus solution was mixed in a ratio of 1:1, placed in a 15℃ CO2 incubator for 1h, inoculated into a 96-well plate monolayer of EPC cells, and incubated in a 15℃ CO2 incubator for 1h. The cell culture medium was discarded and replaced with 100μL of cell maintenance medium per well. The 96-well plate was placed in a static culture at 15℃ and observed for 7 days. The number of wells with and without lesions was recorded. The highest dilution of serum that inhibited 50% of the cytopathic effect was used as the serum neutralization titer, and the serum neutralization antibody titer was calculated according to the Reed-Muench method.

[0062] The IHNV virus solution was cultured in EPC cells at different dilution multiples for 7 days and the CPE changes were observed. According to the Read-Muench method, the titer of IHNV virus was 10 -5.79 TCID 50 / mL. The IHNV neutralizing antibody titer of 10 rainbow trout in the immunization group and the control group was determined. The neutralizing antibody titer of the immunization group was 54.95±6.76, and no IHNV neutralizing antibody was detected in the control group. The neutralizing antibody titer of the immunization group was significantly different from that of the control group (P<0.01).

[0063] So far, the technical solutions of the present invention have been described in conjunction with the preferred embodiments shown in the accompanying drawings. However, it is easy for those skilled in the art to understand that the protection scope of the present invention is obviously not limited to these specific embodiments. Without departing from the principle of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will fall within the protection scope of the present invention.

[0064]

[0065]

[0066]

[0067]

[0068]

Claims

1. A construction method of infectious hematopoietic necrosis virus-Aeromonas salmonicidal vector two-combination vaccine, It is characterized by, Here's how it's built: a. According to the J-type IHNV-G protein gene sequence (serial number: MT242597), codon optimization was performed based on the codon preference of the Aeromonas salmonicida genome and the optimized gene IHNV-G-A was synthesized; b. Design the optimized primer sequence of the IHNV-G protein gene fragment; c. Use the optimized gene IHNV-G-A as a PCR template to amplify the IHNV-G protein gene; d. The amplification product is detected by 1.0% agarose gel electrophoresis, recovered, connected to the pGEX-4T-1 vector and verified by sequencing, to obtain the IHNV G protein expression plasmid pGEX-4T-1-G; e. Use electroporation method to transfer the recombinant plasmid pGEX-4T-1-G into the competent cell SC18032201, and obtain the successfully transformed positive transformant SC18032201-G; f. Induce SC18032201-G to express recombinant protein under optimal induction expression conditions, use 5‰ formaldehyde to inactivate for 24 hours, and dilute with PBS to a final concentration of approximately 1×10 9 cell / mL in Montanide TM ISA 763A VG is used as adjuvant to prepare oil emulsified vaccine.

2. The construction method of the infectious hematopoietic necrosis virus-Aeromonas salmonicidal vector two-combination vaccine as claimed in claim 1, It is characterized by, The optimized gene IHNV-G-A sequence is CAGACCGTCCCGCCGGATACCGCCAGCGAGAGCGACCAGCCGACCTGGAGCAACCCCCTGTTCACCTACCCCGAGGGCTGCACCCTGGATAAGCTGAGCAAAGTGAATGCCAGCCAGCTGCGCTGCCCGCGCATCTTCGACGATGAGAACCG CGGGCTGATCTCCTACCCCGCCAGCATCCGCAGCCTGGCCGTGGGCAATGACCTGGGCGCCATCCACACCCAGGGGAACTATATCCATAAGGTGCTGTACCGCACCATCTGCAGCACCGGCTTCTTCGGCGGCCAGACCATCGAGAAGGTCCTGGTGGAGATGAAGCTGA GCACCCGCGAGGCCGGCGCCTACGATACCACCACCGCCGCCGCCCTGTACTTTCCGGCCCCCCGCTGTCAGTGGTACACCGATAACGTGCAGAACGATCTGATCTTCTACTACACCACCCAGAAGAGCGTCCTGCGGGACCCGTACACCCGCGATTTCCTGGATTCCGA TTTCGTCGGCGGCAAGTGCACCAAGAGCCCGTGCCAGACCCACTGGAGCAACGTGGTCTGGATCGGGGATGCCGGCATCCCGGCCTGCGACGCCAGCCCGGAGATCAACGGCCACCTGTTTGTCGACAAGATCAGCAGCCGGGCCGTGAAGGCCACCAGCTACGGCCACC ACCCCTGGGGCCTGCATCGGGCCTGCATGATCGAGTTTTGCGGCAAGCAGTGGATCCGCACCGATCTCGGGGACCTCATCTCCGTGGGCTATAATAGCGGCGCCAAGACCCTGAGCTTCCCGAAGTGTGAGGATGAGACCGTGGGCATGCGCGGCAACCTGGACGATTT CGCCTACCTGGACGACCTGGTGAAGGCGTCGGAGAGCCGCGAGGAGTGCCTGGAGGCCCATGCCGAGATCATCAGCACCAACAGCGTGACCCCCTACCTGCTGTCCAAGTTCCGCAGCCCGCATCCGGGCATCAACGACGTGTACGCCATGCACAAGGGCAGCATCTACC ACGGCATGTGCATGACCGTGGCCGTCGATGAGGTGAGCAAGGATCGCACCACCTACCGCGCCCACCATGCCACCAACTTCACCAAGTGGGAGCGCCCCTTCGGCGATGAGTGGGAGGGCTTCCACGGCCTGCATGGCAATAACATCACCATCATCCCGGATCTGGAGAA GTACGTCGCACAATATAAGATGAGTATGATGGAGCCCATGGGCATCAAGAGCGTACCCCATCCAAGCATTCTCGCGTTTTATAATGAGACCGAAGTGAGCGGTATCAGCATTCGCAAGCTGGATAGCTTCGATCTGCAGAGCTTGCATCATCACCACCATCATCATTGA.

3. The construction method of the infectious hematopoietic necrosis virus-Aeromonas salmonicidal vector two-combination vaccine as claimed in claim 1, It is characterized by, The primer sequence is: Upstream primer IHNV-of-pGEX-4T-1-for-f: 5′-CGCGTGGATCCCCGGCAGACCGTCCCGCC GGATAC-3′, Downstream primer IHNV-of-pGEX-4T-1-for-r:5′-GTCGACCCGGGAATTTTATCAAGATGATGGTGGTGATGATGCAAGC-3′.

4. The construction method of the infectious hematopoietic necrosis virus-Aeromonas salmonicidal vector two-combination vaccine as claimed in claim 1, It is characterized by, The PCR amplification procedure is: The amplification program included pre-denaturation at 98°C for 1 minute; denaturation at 98°C for 10 seconds; annealing at 58°C for 5 seconds, extension at 72°C for 15 seconds, 35 cycles; and full extension at 72°C for 7 minutes.

5. The construction method of the infectious hematopoietic necrosis virus-Aeromonas salmonicidal vector two-combination vaccine as claimed in claim 1, It is characterized by, The optimal protein induction conditions for the recombinant strain SC18032201-G are: 0.2mM IPTG, 28°C for 8 hours.